[Exhibit A]
T2 Biosystems Reminds Stockholders to Vote at the Upcoming Annual Meeting
LEXINGTON, Mass., May 25, 2021 (GLOBE NEWSWIRE)T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing
pathogens, today reminded stockholders to vote at the upcoming 2021 Annual Meeting of Stockholders to be held on June 25, 2021. The T2 Biosystems Board of Directors unanimously supports each stockholder proposal on the proxy and encourages all
stockholders to vote for these proposals.
The Companys President and CEO, John Sperzel, has released a statement communicating to stockholders the
importance of the proposals and their potential impact on the Company. The video statement can be found on the Investor Relations section of the Companys website at investors.t2biosystems.com.
T2 Biosystems, Inc. will be holding its Annual Meeting virtually on June 25, 2021 at 9:00 a.m. Eastern Time
at www.virtualshareholdermeeting.com/TTOO2021. T2 Biosystems stockholders of record as of April 28, 2021 are entitled to vote at the Annual Meeting.
T2 Biosystems definitive proxy materials, 2020 Annual Report to Stockholders and other relevant information can be found at www.sec.gov.
If you have any questions about how to vote your shares, or need additional assistance, please contact MacKenzie Partners at 1-800-322-2885.
About T2
Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of
care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems products include the T2Dx® Instrument,
T2Candida® Panel, the T2Bacteria® Panel, the T2ResistanceTM Panel, and the T2SARS-CoV-2 Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®)
technology. T2 Biosystems has an active pipeline of future products, including the T2CaurisTM Panel, and T2Lyme TM Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance
markers, and biothreat pathogens.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in
this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the stockholder proposals and their potential impact, as well as statements that
include the words expect, intend, plan, believe, project, forecast, estimate, may, should, anticipate, and similar statements of
a future or forward looking nature. These forward-looking statements are based on managements current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important
factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any
inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer
testimonials; (f) accurately predict